Kentucky marijuana officials are urging lawmakers to broaden the list of medical conditions that qualify patients for a medical cannabis card. In a letter sent Thursday to top legislative leaders, the Office of Medical Cannabis (OCM) outlined its case for expanding eligibility under the state’s relatively new program.
The OCM’s request comes as the program, which launched in early 2023, has seen steady enrollment but faces criticism for its limited qualifying conditions. Currently, patients with conditions such as cancer, chronic pain, epilepsy, and post-traumatic stress disorder are eligible, but advocates argue that many other ailments should be included. The letter did not specify which conditions it seeks to add, but sources indicate that conditions like anxiety, depression, and opioid use disorder are under consideration.
State Representative Jason Nemes, a key sponsor of the original medical marijuana legislation, expressed support for the expansion. He added that he plans to introduce two measures this session aimed at widening access and called on fellow lawmakers to support the effort. “We’ve seen the benefits of medical cannabis for patients across the state, and it’s time to ensure that more Kentuckians can access this treatment,” Nemes said in a statement.
The broader marijuana industry, including established businesses like Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF), will be glad when the expansion takes effect. Curaleaf, a leading multistate operator, has a presence in Kentucky through its cultivation and dispensary operations. The company has been vocal about the need for regulatory frameworks that allow for growth and patient access.
The push for expansion reflects a national trend as more states reconsider their medical marijuana programs. According to the National Conference of State Legislatures, 38 states have legalized medical cannabis, but qualifying conditions vary widely. Kentucky’s program, while relatively new, is seen as conservative compared to neighboring states like Illinois and Michigan, which have more expansive lists.
If the expansion is approved, it could significantly increase the number of patients in the program, which currently has about 10,000 registered patients. This would likely boost demand for cannabis products and create economic opportunities for businesses in the supply chain, from cultivators to retailers. However, opponents of expansion argue that broadening eligibility could lead to abuse and undermine the program’s medical integrity.
The legislative session is expected to last through March, and the OCM’s letter is likely to spark debate among lawmakers. The outcome could have implications not only for Kentucky patients but also for the broader cannabis industry, which is watching the state as a bellwether for conservative-leaning states weighing medical marijuana reforms.
